Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2023 2
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Immune Checkpoint Inhibitor-Induced Dermatitis"
Page 1
PD-1/PD-L1 inhibitor-induced immune thrombocytopenia: A pharmacovigilance study and systematic review.
Moore DC, Elmes JB, Arnall JR, Strassel SA, Patel JN. Moore DC, et al. Int Immunopharmacol. 2024 Mar 10;129:111606. doi: 10.1016/j.intimp.2024.111606. Epub 2024 Feb 14. Int Immunopharmacol. 2024. PMID: 38359661
INTRODUCTION: Programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) immune checkpoint inhibitors (ICIs) are used for a variety of cancers and are associated with a risk of developing immune-related adverse events, most common …
INTRODUCTION: Programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) immune checkpoint inhibi …
Immune checkpoint inhibitor-induced epidermal necrolysis: A narrative review evaluating demographics, clinical features, and culprit medications.
Satoh TK, Neulinger MM, Stadler PC, Aoki R, French LE. Satoh TK, et al. J Dermatol. 2024 Jan;51(1):3-11. doi: 10.1111/1346-8138.17039. Epub 2023 Nov 30. J Dermatol. 2024. PMID: 38031902 Review.
Immune checkpoint inhibitors (ICIs) have transformed cancer treatment but can cause immune-related adverse events (irAEs). ...Our findings highlight the frequency and severity of ICI-induced SJS/TEN and the urgent need for predictive molecular biomarke …
Immune checkpoint inhibitors (ICIs) have transformed cancer treatment but can cause immune-related adverse events (irAE …
Use of a topical Janus kinase inhibitor in immune checkpoint inhibitor-induced eczematous reaction: a case report.
Powers CM, Verma H, Orloff J, Piontkowski AJ, Tiersten A, Lamb A, Gulati N. Powers CM, et al. J Dermatolog Treat. 2024 Dec;35(1):2336118. doi: 10.1080/09546634.2024.2336118. Epub 2024 Apr 2. J Dermatolog Treat. 2024. PMID: 38565207 Free article.
In this report, we describe the case of a 28-year-old female with bilateral breast cancer in the setting of a BRCA1 mutation, who presented to dermatology with an eczematous reaction, ultimately diagnosed as a cutaneous immune-related adverse event (cirAE) secondary to an …
In this report, we describe the case of a 28-year-old female with bilateral breast cancer in the setting of a BRCA1 mutation, who presented …
Immune checkpoint inhibitor-induced lichenoid drug eruption-sparing scar burns.
Truong K, Chamberlin CV, Kim J, Carlino MS, Araujo RR. Truong K, et al. Australas J Dermatol. 2024 Mar;65(2):163-166. doi: 10.1111/ajd.14192. Epub 2023 Nov 27. Australas J Dermatol. 2024. PMID: 38009870
The authors present a striking case of a patient experiencing a lichenoid drug eruption secondary to immunotherapy, curiously sparing scarred skin from past burns. We observed vastly higher amounts of inflammatory lymphoid cells staining for PD-1; 70% in skin with a lichen …
The authors present a striking case of a patient experiencing a lichenoid drug eruption secondary to immunotherapy, curiously sparing scarre …